Search Results - "Winthrop, Kevin L."

Infection Risk and Safety of Corticosteroid Use by Youssef, Jameel, MD, Novosad, Shannon A., MD, Winthrop, Kevin L., MD, MPH

“…Corticosteroids are frequently used to treat rheumatic diseases. Their use comes with several well-established risks, including osteoporosis, avascular…”
Get full text

Nontuberculous Mycobacteria Infections in Immunosuppressed Hosts by Henkle, Emily, PhD, MPH, Winthrop, Kevin L., MD, MPH

“…Diseases and therapies that reduce cell-mediated immunity increase the risk of nontuberculous mycobacterial (NTM) disease. Extrapulmonary NTM disease,…”
Get full text

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database by Taylor, Peter C, Takeuchi, Tsutomu, Burmester, Gerd R, Durez, Patrick, Smolen, Josef S, Deberdt, Walter, Issa, Maher, Terres, Jorge Ross, Bello, Natalia, Winthrop, Kevin L

“…To report long-term safety from the completed extension trial of baricitinib, an oral selective Janus kinase inhibitor, in patients with active rheumatoid…”
Get more information

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials by Cohen, Stanley B, Tanaka, Yoshiya, Mariette, Xavier, Curtis, Jeffrey R, Lee, Eun Bong, Nash, Peter, Winthrop, Kevin L, Charles-Schoeman, Christina, Thirunavukkarasu, Krishan, DeMasi, Ryan, Geier, Jamie, Kwok, Kenneth, Wang, Lisy, Riese, Richard, Wollenhaupt, Jürgen

“…Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two…”
Get more information

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline by Daley, Charles L, Iaccarino, Jonathan M, Lange, Christoph, Cambau, Emmanuelle, Wallace, Jr, Richard J, Andrejak, Claire, Böttger, Erik C, Brozek, Jan, Griffith, David E, Guglielmetti, Lorenzo, Huitt, Gwen A, Knight, Shandra L, Leitman, Philip, Marras, Theodore K, Olivier, Kenneth N, Santin, Miguel, Stout, Jason E, Tortoli, Enrico, van Ingen, Jakko, Wagner, Dirk, Winthrop, Kevin L

“…Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both…”
Get full text

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline by Daley, Charles L, Iaccarino, Jonathan M, Lange, Christoph, Cambau, Emmanuelle, Wallace, Richard J, Andrejak, Claire, Böttger, Erik C, Brozek, Jan, Griffith, David E, Guglielmetti, Lorenzo, Huitt, Gwen A, Knight, Shandra L, Leitman, Philip, Marras, Theodore K, Olivier, Kenneth N, Santin, Miguel, Stout, Jason E, Tortoli, Enrico, van Ingen, Jakko, Wagner, Dirk, Winthrop, Kevin L

“…Abstract Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect…”
Get full text

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy by Winthrop, Kevin L., Curtis, Jeffrey R., Lindsey, Stephen, Tanaka, Yoshiya, Yamaoka, Kunihiro, Valdez, Hernan, Hirose, Tomohiro, Nduaka, Chudy I., Wang, Lisy, Mendelsohn, Alan M., Fan, Haiyun, Chen, Connie, Bananis, Eustratios

“…Objective Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster (HZ), and the risk appears to be increased in patients treated with…”
Get full text

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline by Daley, Charles L, Iaccarino, Jonathan M, Lange, Christoph, Cambau, Emmanuelle, Wallace, Richard J, Andrejak, Claire, Böttger, Erik C, Brozek, Jan, Griffith, David E, Guglielmetti, Lorenzo, Huitt, Gwen A, Knight, Shandra L, Leitman, Philip, Marras, Theodore K, Olivier, Kenneth N, Santin, Miguel, Stout, Jason E, Tortoli, Enrico, van Ingen, Jakko, Wagner, Dirk, Winthrop, Kevin L

“…Abstract Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect…”
Get full text

Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008-2015 by Winthrop, Kevin L, Marras, Theodore K, Adjemian, Jennifer, Zhang, Haixin, Wang, Ping, Zhang, Quanwu

“…Estimating the annual incidence and prevalence of nontuberculous mycobacterial (NTM) lung disease may assist in improving understanding of the public health…”
Get full text

Nontuberculous Mycobacterial Disease Prevalence and Risk Factors: A Changing Epidemiology by Cassidy, P. Maureen, Hedberg, Katrina, Saulson, Ashlen, McNelly, Erin, Winthrop, Kevin L

“…Background. Nontuberculous mycobacteria (NTM) are important human pathogens, yet little is known about disease prevalence in the United States. Reports suggest…”
Get full text

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis by Sepriano, Alexandre, Kerschbaumer, Andreas, Bergstra, Sytske Anne, Smolen, Josef S, van der Heijde, Désirée, Caporali, Roberto, Edwards, Christopher J, Verschueren, Patrick, de Souza, Savia, Pope, Janet, Takeuchi, Tsutomu, Hyrich, Kimme, Winthrop, Kevin L, Aletaha, Daniel, Stamm, Tanja, Schoones, Jan W, Landewé, Robert B M

“…To perform a systematic literature review (SLR) concerning the safety of synthetic(s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) to…”
Get more information

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis by Winthrop, Kevin L, Silverfield, Joel, Racewicz, Arthur, Neal, Jeffrey, Lee, Eun Bong, Hrycaj, Pawel, Gomez-Reino, Juan, Soma, Koshika, Mebus, Charles, Wilkinson, Bethanie, Hodge, Jennifer, Fan, Haiyun, Wang, Tao, Bingham, 3rd, Clifton O

“…To evaluate tofacitinib's effect upon pneumococcal and influenza vaccine immunogenicity. We conducted two studies in patients with rheumatoid arthritis using…”
Get more information

Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis by Henkle, Emily, Curtis, Jeffrey R, Chen, Lang, Chan, Benjamin, Aksamit, Timothy R, Daley, Charles L, Griffith, David E, Winthrop, Kevin L

“…Non-cystic fibrosis (CF) bronchiectasis ("bronchiectasis") is a chronic airway disease for which little data exist to inform treatment decisions. We sought to…”
Get full text

Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease by Olivier, Kenneth N, Griffith, David E, Eagle, Gina, McGinnis, 2nd, John P, Micioni, Liza, Liu, Keith, Daley, Charles L, Winthrop, Kevin L, Ruoss, Stephen, Addrizzo-Harris, Doreen J, Flume, Patrick A, Dorgan, Daniel, Salathe, Matthias, Brown-Elliott, Barbara A, Gupta, Renu, Wallace, Jr, Richard J

“…Lengthy, multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease. In this phase II study, we…”
Get full text

Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department by Shorstein, Neal H., MD, Winthrop, Kevin L., MD, Herrinton, Lisa J., PhD

“…Purpose To evaluate post-cataract-surgery endophthalmitis rates in relation to changing practice patterns in antibiotic administration. Setting Kaiser…”
Get full text

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis by Kerschbaumer, Andreas, Sepriano, Alexandre, Bergstra, Sytske Anne, Smolen, Josef S, van der Heijde, Désirée, Caporali, Roberto, Edwards, Christopher John, Verschueren, Patrick, de Souza, Savia, Pope, Janet E, Takeuchi, Tsutomu, Hyrich, Kimme L, Winthrop, Kevin L, Aletaha, Daniel, Stamm, Tanja A, Schoones, Jan W, Landewé, Robert B M

“…To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic drugs) and inform the taskforce of the 2022 update of the European Alliance of…”
Get more information

Surveillance of Extrapulmonary Nontuberculous Mycobacteria Infections, Oregon, USA, 2007-2012 by Henkle, Emily, Hedberg, Katrina, Schafer, Sean D, Winthrop, Kevin L

“…Limited data are available describing extrapulmonary nontuberculous mycobacteria (NTM) infections in the general population. We describe results from statewide…”
Get full text

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program by Simpson, Eric L., Silverberg, Jonathan I., Nosbaum, Audrey, Winthrop, Kevin L., Guttman-Yassky, Emma, Hoffmeister, Karin M., Egeberg, Alexander, Valdez, Hernan, Zhang, Min, Farooqui, Saleem A., Romero, William, Thorpe, Andrew J., Rojo, Ricardo, Johnson, Susan

“…Background Pivotal phase III studies demonstrated that abrocitinib, an oral, once-daily, JAK1-selective inhibitor, is effective treatment for…”
Get full text

Treatment of Mycobacterium abscessus Infection by Novosad, Shannon A, Beekmann, Susan E, Polgreen, Philip M, Mackey, Kate, Winthrop, Kevin L

“…Mycobacterium abscessus is often resistant to multiple antimicrobial drugs, and data supporting effective drugs or dosing regimens are limited. To better…”
Get full text

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force by Strehl, Cindy, Bijlsma, Johannes W J, de Wit, Maarten, Boers, Maarten, Caeyers, Nele, Cutolo, Maurizio, Dasgupta, Bhaskar, Dixon, William G, Geenen, Rinie, Huizinga, Tom W J, Kent, Alison, de Thurah, Annette Ladefoged, Listing, Joachim, Mariette, Xavier, Ray, David W, Scherer, Hans U, Seror, Raphaèle, Spies, Cornelia M, Tarp, Simon, Wiek, Dieter, Winthrop, Kevin L, Buttgereit, Frank

“…There is convincing evidence for the known and unambiguously accepted beneficial effects of glucocorticoids at low dosages. However, the implementation of…”
Get more information